# Zydus receives Final Approvals from the USFDA for Dexamethasone Tablets USP, 0.5 mg, 0.75 mg, 1.5 mg, 4 mg and 6 mg and Dexamethasone Tablets USP, 2 mg

*Ahmedabad, India, February 08, 2024*

Zydus Lifesciences Limited (including its subsidiaries/affiliates, hereafter referred to as "Zydus") has received final approvals from the United States Food and Drug Administration (USFDA) to manufacture and market Dexamethasone Tablets USP, 0.5 mg, 0.75 mg, 1.5 mg, 4 mg and 6 mg (USRLD: Decadron® Tablets) and Dexamethasone Tablets USP, 2 mg (USRLD: Dexamethasone Tablets).

Dexamethasone is used to treat a number of different conditions, such as inflammation (swelling), severe allergies, adrenal problems, arthritis, asthma, blood or bone marrow problems, kidney problems, skin conditions, and flare-ups of multiple sclerosis. The products will be manufactured at the group's formulation manufacturing facility at Baddi, Himachal Pradesh.

Dexamethasone Tablets USP, 0.5 mg, 0.75 mg, 1.5 mg, 4 mg and 6 mg had annual sales of USD 22 mn and Dexamethasone Tablets USP, 2 mg has annual sales of USD 6 mn in the United States (IQVIA Dec. Nov. 2023).

The group now has 386 approvals and has so far filed over 448* ANDAs since the commencement of the filing process in FY 2003-04.

(*as of 30th September 2023)

###

PRESS RELEASE

For further information please contact :
**The Corporate Communications Department**

**Zydus Lifesciences Limited**
(formerly known as Cadila Healthcare Limited)
**Regd. Office** : 'Zydus Corporate Park',
Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),
Nr. Vaishnodevi Circle, S. G. Highway, Ahmedabad 382
481, Gujarat, India. | Phone : +91-79-71800000,
+91-79-48040000 | website : www.zyduslife.com
CIN : L24230GJ1995PLC025878